Digital Rehabilitation for COPD Patients: NICE recommends

By HEOR Staff Writer

January 26, 2024

A Focus on Long-Term Respiratory Conditions:

Chronic Obstructive Pulmonary Disease (COPD) is a long-term respiratory condition affecting over 1.17 million people in England alone. In spite of the prevalence, it’s estimated that an additional 2 million individuals remain undiagnosed. COPD, which includes chronic bronchitis and emphysema, is characterised by breathlessness, persistent coughing, wheezing, and frequent chest infections. Triggers include respiratory tract infections, smoking, and environmental pollutants.

The Impact of COPD on Hospital Admissions

Exacerbations of COPD are the second most prevalent cause of emergency hospital admissions in the United Kingdom (UK), accounting for one in eight of all hospitalisations. The increased shortness of breath or coughing that occurs as a result of these flare-ups frequently calls for immediate medical attention at a hospital.

The Role of Pulmonary Rehabilitation in COPD Management

Pulmonary rehabilitation has proven effective in the UK in managing COPD according to the National Health Service (NHS). Approximately 90% of patients who complete an in-person programme, experienced increased exercise capacity and equally important, improved quality of life. However, these programmes are currently only offered to 13% of eligible patients in the UK, predominantly those with severe COPD.

Introducing Digital Rehabilitation Technologies for COPD

The medical technologies advisory committee of National Institute for Health and Care Excellence (NICE) recommends two digital technologies, MyCOPD and SPACE for COPD, for pulmonary rehabilitation treatments. These platforms offer fitness regimens and educational sessions, enabling COPD patients to manage their condition at their convenience. While they don’t replace traditional in-person rehabilitation, they offer a valuable option for individuals without access to local facilities and to those who prefer not to have in-person treatment. 

Reference url

Recent Posts

Advancing the Biosimilar Approval Framework: A Shift Towards Analytical Comparability

By HEOR Staff Writer

April 6, 2026

Below we highlight how the European Medicines Agency (EMA) is reshaping the biosimilar approval framework by prioritising advanced analytical characterisation over traditional comparative efficacy studies. A recently finalized reflection paper outlines a science-based, tailored clinical develo...
Current Challenges in Outcome Transparency Healthcare in Dutch Medical Specialist Care
In this update we highlight the persistent shortcomings in outcome transparency in Netherland's healthcare system. The 2026 baseline measurement report published by Zorginstituut Nederland and Patiëntenfederatie Nederland shows that national ambitions for transparency of care outcomes in medical ...
European Immunotherapy Approval for Ovarian Cancer: KEYTRUDA’s New Role in Treating PD-L1-P...
Immunotherapy ovarian cancer treatment has taken a major step forward in Europe. The European Commission has approved KEYTRUDA (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for adults with PD-L1 CPS ≥1 platinum-resistant recurrent ovarian, fallopian tube, or primary...